Table 4. Therapy at baseline and month-12 visit.

	Overall (n = 729)	HTN (n = 392)	DN (n = 116)	GN (n = 126)	TIN (n = 69)	PKD (n = 26)	P
LSD (%)
Baseline	22.8	25.6	18.0	19.3	23.1	16.7	0.354
Month 12	26.2	26.4	31.5*	19.3	29.2	25.0	0.301
BP lowering drugs (n)
Baseline	2.2±1.3	2.5±1.2	2.5±1.2	1.7 ±1.3	1.0±1.1	1.6±1.6	<0.0001
Month 12	2.7±1.4*	2.8±1.2*	3.3±1.5*	2.5±1.4*	1.5±1.4*	2.0±1.4*	<0.0001
RAS inhibitors (%)
Baseline	74.9	82.1	77.4	67.5	54.3	69.2	<0.0001
Month 12	85.3*	88.8*	75.6	88.9*	60.0*	76.9	<0.0001
B-blockers (%)
Baseline	27.4	33.9	30.4	16.7	5.8	24.0	<0.0001
Month 12	36.7*	41.1*	46.1*	27.8*	14.5*	32.0	<0.0001
CCBs (%)
Baseline	34.9	39.0	48.7	20.6	17.4	28.0	<0.0001
Month 12	43.9*	48.7*	60.9*	26.2	24.6	32.0	<0.0001
Furosemide (%)
Baseline	23.1	25.0	33.9	19.0	8.7	4.0	<0.0001
Month 12	34.3*	34.4*	51.3*	34.9*	11.6	12.0	<0.0001
ESA (%)
Baseline	3.0	2.6	0.9	5.6	4.3	3.8	0.256
Month 12	14.4*	14.3*	19.1*	12.7*	12.9*	7.7	0.482
Iron supplement (%)
Baseline	4.1	4.3	3.5	1.6	8.7	4.0	0.210
Month 12	18.2*	16.3*	26.1*	17.5*	14.5	24.0	0.136
Statins (%)
Baseline	30.0	31.1	45.2	26.2	10.1	16.9	<0.0001
Month 12	43.7*	45.7*	55.7*	38.1*	29.0*	28.0	0.002
Vitamin D (%)
Baseline	4.0	3.1	0.9	7.1	8.7	4.0	0.026
Month 12	13.9*	12.5*	9.6*	21.4*	14.5	16.0	0.074
P binders (%)
Baseline	0.3	0.3	0	0.8	0	0	0.769
Month 12	2.1*	1.3	4.3	0.8	4.3	4.0	0.115

Data are mean±SD or % of patients and (95%CI). RAS, renin-angiotensin system; BP, blood pressure; LSD, low salt diet (UNaV <100 mmol/24h); ESA, erythropoiesis stimulating agents.

* P<0.05 versus baseline